This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Janssen Pharmaceuticals Korea.
KRW1100 = $US1
Reference
Park HY, et al. Cost-Effectiveness of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis in the Republic of Korea. Clinical Therapeutics : 19 Feb 2016. Available from: URL: http://dx.doi.org/10.1016/j.clinthera.2016.01.023
Rights and permissions
About this article
Cite this article
Bedaquiline cost effective for multi-drug resistant TB in Korea. PharmacoEcon Outcomes News 748, 9 (2016). https://doi.org/10.1007/s40274-016-2860-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-2860-4